Invention Grant
- Patent Title: Antibodies against claudin 18.2 useful in cancer diagnosis
-
Application No.: US16037759Application Date: 2018-07-17
-
Publication No.: US11976130B2Publication Date: 2024-05-07
- Inventor: Ugur Sahin , Ozlem Tureci , Rita Mitnacht-Kraus , Stefan Woll
- Applicant: Ganymed Pharmaceuticals AG , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- Applicant Address: DE Mainz
- Assignee: Astellas Pharma Inc.,TRON—Translationale Onkologie an der Universitätsmedizin der Johannes
- Current Assignee: Astellas Pharma Inc.,TRON—Translationale Onkologie an der Universitätsmedizin der Johannes
- Current Assignee Address: JP Toyko; DE Gutenberg-Universität Mainz
- Agency: Neal, Gerber & Eisenberg LLP
- Priority: WO TEP2012001991 2012.05.09
- The original application number of the division: US15227565 2016.08.03
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07K16/28 ; G01N33/574
Abstract:
The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
Public/Granted literature
- US20180319891A1 ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS Public/Granted day:2018-11-08
Information query
